ReviewPatient related outcome measures2018
Immune thrombocytopenia: improving quality of life and patient outcomes.
Review in Patient related outcome measures, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- American Society of Hematology 2019 guidelines for immune thrombocytopenia.Blood advances · 2019Guideline
- Management strategies for newly diagnosed immune thrombocytopenia in Italian AIEOP Centres: do we overtreat? Data from a multicentre, prospective cohort study.Blood transfusion = Trasfusione del sangue · 2020Trial
- Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program.Journal of the advanced practitioner in oncology · 2026Article
- Association Between Bleeding Severity and Quality of Life in Adults with Immune Thrombocytopenia.Juntendo medical journal · 2026Article
- A Qualitative Study on Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia.The patient · 2026Article
- Rilzabrutinib for the Treatment of Immune Thrombocytopenia.European journal of haematology · 2025Review
- Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan.International journal of hematology · 2025Article
- Diagnosis and Management of Immune Thrombocytopenia in Paediatrics: A Comprehensive Review.Cureus · 2024Review
- Treatment outcomes and adherence to treatment in patients with immune thrombocytopenia in two Ethiopian teaching hospitals: a retrospective cohort study.Scientific reports · 2024Article
- Health-related quality of life and complications of corticosteroid treatment in patients with immune thrombocytopenia in two teaching hospitals in Ethiopia: a cross-sectional study.Frontiers in medicine · 2024Article
- Article
- Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia.Blood advances · 2023Article
- Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis.EClinicalMedicine · 2023Article
- Reliability and validity of the Amharic version of immune thrombocytopenia life quality index tool for assessment of the health-related quality of life in Ethiopian patients of immune thrombocytopenia: Cross-sectional study.SAGE open medicine · 2023Article
- RilzabrutinibTherapeutic advances in hematology · 2023Article
- Possible Targets to Reduce Fatigue in Chronic Immune Thrombocytopenia Patients - An Explorative Study.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.Blood advances · 2022Article
- Observational
- Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany.Acta haematologica · 2022Observational
- Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia.Advances in therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is an immune-mediated disorder characterized by a reduced platelet count and patients may develop bruising or mucosal bleeding. Since 2003, generic health-related quality of life (HRQoL) measures have been applied and ITP-specific measures developed, alongside trials of novel therapeutic agents. These have identified significant morbidity in patients with ITP, including fatigue, fear of bleeding and a negative impact on role, social and work activities. This review critically evaluates HRQoL data in adults and children with ITP. It also considers the impact of treatment and how patient-reported outcomes might be applied to care to optimize patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.